Available update of the Strategic Research and Innovation Agenda: a vision for Nanomedicine in Europe for 2016-2030
ETPN is proud to announce that the new version of the SRIA for Nanomedicine is available and can be dowloaded by clicking here.
This SRIA update has been designed in close collaboration with Euro Nanomed with the objective to reflect the main current and future challenges that the European Community in nanomedicine is facing. The integration of Innovation as a fully-fledged element of the ETP Nanomedicine shows the importance for the nanomedicine to reach the next steps in the translation process towards the market(s).
The SRIA is intended to provide a framework for the fruitful deployment of innovative solutions for healthcare and to provide the ecosystem, including European, national and regional public authorities with roadmaps and priorities for research.
Beyond recommendations for research topics, the focus is set on translability of research results, i.e. their adequacy with clinical but also industrial needs and requirements. In 2013, the ETP Nanomedicine published a White Paper “Contribution of Nanomedicine to Horizon 2020” setting the groundwork to manage the efficient translation of nanotechnology from a Key Enabling Technology (KET) into new and innovative medical products. Two years later the concrete implementation of the recommendations formulated in this strategic document started with the launch of the EU-Nano-Characterisation Lab, of 3 pilots lines for GMP manufacturing of nanomedicine and well as with the constitution of the Translation Advisory Board in the framework of the ENATRANS Coordination and Support Action.
This document has a particular importance as ETPN has recently celebrated its 10th anniversary and should also reflect the tremendous advancements and progress done since its inception.
Key recommendations of the SRIA update are:
- to focus on unmet medical needs where Nanomedicine can make the difference by providing currently lacking diagnostic and therapeutic options,
- to facilitate the matching of nanotechnology features with other Key Enabling Technologies (KETs) for new smart and connected products and devices
- to optimise the implementation of medical innovations into the healthcare systems by balancing benefit for patients with cost constrains of the healthcare system and industrial return on investment
- to sustain or even improve competitiveness of European healthcare economy at the global market